| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
Departments of 1 Radiation Oncology and 2 Pathology, 3 Comprehensive Cancer Center and Department of Laboratory Medicine, and 4 Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, California and 5 Lawrence Berkeley National Laboratory, Berkeley, California
Requests for reprints: Catherine Park, Department of Radiation Oncology, University of California at San Francisco/Mt. Zion Cancer Center, 1600 Divisadero Street H1031, San Francisco, CA 94143-1708. Phone: 415-353-7186; Fax: 415-353-9883; E-mail: Catherine.park{at}ucsf.edu.
Aberrant microenvironments and loss of balance in cell-extracellular matrix signaling are associated with breast cancer invasion, metastasis, and resistance to therapy. We have recently shown that increased ß1 integrin signaling is involved in malignant progression and that inhibitory antibody to ß1 integrin leads to selective apoptosis and decreased proliferation in three-dimensional cultures and in xenograft models of breast cancer in vivo. To investigate the clinical importance of these findings, in the present study we examined the expression of ß1 integrin and extracellular ß1 integrin ligands fibronectin and laminin-1 in a cohort of 249 breast cancer patients who had a median follow-up of 8.4 years. Among the 149 scorable cases, the highest ß1 integrin intensity score (3+ versus 02+) was associated with significantly decreased 10-year overall survival of 48% versus 71% (P < 0.03) and decreased disease-free survival of 50% versus 80% (P < 0.05). Importantly, high fibronectin expression was associated with decreased overall and disease-free survival on univariate analysis (P < 0.04) and ß1 integrin intensity score was significantly correlated with fibronectin expression (Kendall's tau-b = 0.19; P = 0.03). In a multivariate Cox proportional hazards model, ß1 integrin intensity score remained a significant independent predictor of overall survival [hazard ratio (HR), 1.69; 95% confidence interval (95% CI), 1.192.38; P < 0.003] and disease-free survival (HR, 1.87; 95% CI, 1.212.88; P < 0.005). These findings show that ß1 integrin expression has potential prognostic value in invasive breast cancer and that coexpression of fibronectin may help identify patients with more aggressive tumors who may benefit from targeted therapy. [Cancer Res 2007;67(2):65964]
This article has been cited by other articles:
![]() |
D. Lesniak, Y. Xu, J. Deschenes, R. Lai, J. Thoms, D. Murray, S. Gosh, J. R. Mackey, S. Sabri, and B. Abdulkarim {beta}1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer Cancer Res., November 15, 2009; 69(22): 8620 - 8628. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Chiu, D.-C. Shieh, K.-M. Tong, C.-P. Chen, K.-C. Huang, P.-C. Chen, Y.-C. Fong, H.-C. Hsu, and C.-H. Tang Involvement of AdipoR receptor in adiponectin-induced motility and {alpha}2{beta}1 integrin upregulation in human chondrosarcoma cells Carcinogenesis, October 1, 2009; 30(10): 1651 - 1659. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-N. Yang, H.-T. Chen, H.-K. Tsou, C.-Y. Huang, W.-H. Yang, C.-M. Su, Y.-C. Fong, W.-P. Tseng, and C.-H. Tang Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor Carcinogenesis, April 1, 2009; 30(4): 566 - 574. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Goel, J. Li, S. Kogan, and L. R Languino Integrins in prostate cancer progression Endocr. Relat. Cancer, September 1, 2008; 15(3): 657 - 664. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Helleman, M. P.H.M. Jansen, K. Ruigrok-Ritstier, I. L. van Staveren, M. P. Look, M. E. Meijer-van Gelder, A. M. Sieuwerts, J. G.M. Klijn, S. Sleijfer, J. A. Foekens, et al. Association of an Extracellular Matrix Gene Cluster with Breast Cancer Prognosis and Endocrine Therapy Response Clin. Cancer Res., September 1, 2008; 14(17): 5555 - 5564. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Park, H. J. Zhang, E. S. Yao, C. J. Park, and M. J. Bissell {beta}1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts Cancer Res., June 1, 2008; 68(11): 4398 - 4405. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Williams, A. J. Engler, R. D. Slone, L. L. Galante, and J. E. Schwarzbauer Fibronectin Expression Modulates Mammary Epithelial Cell Proliferation during Acinar Differentiation Cancer Res., May 1, 2008; 68(9): 3185 - 3192. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Meads, L. A. Hazlehurst, and W. S. Dalton The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance Clin. Cancer Res., May 1, 2008; 14(9): 2519 - 2526. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |